secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2026-09-14T11:12:01+00:00
Accession:  0001104659-26-107253
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata gets FDA Breakthrough Therapy designation for AP-SA02 in S. aureus bacteremia
--------------------------------------------------------------------------------

- FDA granted Breakthrough Therapy designation to AP-SA02 for adjunct treatment of complicated bacteremia caused by MSSA or MRSA.
- Designation based on Phase 1b/2a diSArm data: 100% of AP-SA02 patients maintained clinical response vs 75% on placebo at day 28.
- AP-SA02 dosing every 6h for 5 days was well tolerated; no serious adverse events attributed to the drug.
- AP-SA02 now holds Breakthrough Therapy, Fast Track, and QIDP designations from the FDA.
- CEO Deborah Birx cites potential to become first antibacterial approved on superiority to standard of care.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465926107253/0001104659-26-107253-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465926107253/tm2625289d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-107253

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer